[go: up one dir, main page]

AU6117000A - Novel polynucleotides and method of use thereof - Google Patents

Novel polynucleotides and method of use thereof

Info

Publication number
AU6117000A
AU6117000A AU61170/00A AU6117000A AU6117000A AU 6117000 A AU6117000 A AU 6117000A AU 61170/00 A AU61170/00 A AU 61170/00A AU 6117000 A AU6117000 A AU 6117000A AU 6117000 A AU6117000 A AU 6117000A
Authority
AU
Australia
Prior art keywords
novel polynucleotides
polynucleotides
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU61170/00A
Inventor
Kevin P. Baker
Audrey Goddard
William I. Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AU6117000A publication Critical patent/AU6117000A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU61170/00A 1999-07-26 2000-07-21 Novel polynucleotides and method of use thereof Abandoned AU6117000A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14570199P 1999-07-26 1999-07-26
US60145701 1999-07-26
PCT/US2000/020006 WO2001007611A2 (en) 1999-07-26 2000-07-21 Novel polynucleotides and method for the use thereof

Publications (1)

Publication Number Publication Date
AU6117000A true AU6117000A (en) 2001-02-13

Family

ID=22514171

Family Applications (1)

Application Number Title Priority Date Filing Date
AU61170/00A Abandoned AU6117000A (en) 1999-07-26 2000-07-21 Novel polynucleotides and method of use thereof

Country Status (5)

Country Link
EP (1) EP1196570A2 (en)
JP (1) JP2003505082A (en)
AU (1) AU6117000A (en)
CA (1) CA2378403A1 (en)
WO (1) WO2001007611A2 (en)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2385496A1 (en) * 1999-09-23 2001-03-29 Incyte Genomics, Inc. Molecules for diagnostics and therapeutics
AU7720600A (en) * 1999-09-27 2001-04-30 Eli Lilly And Company Osteoprotegerin regulatory region
CA2392090A1 (en) 1999-11-16 2001-05-25 Merck & Co., Inc. G-protein coupled receptor
WO2001036636A2 (en) * 1999-11-17 2001-05-25 Lexicon Genetics Incorporated Human notch ligand proteins and polynucleotides encoding the same
US6803192B1 (en) 1999-11-30 2004-10-12 Mayo Foundation For Medical Education And Research B7-H1, a novel immunoregulatory molecule
ES2629683T3 (en) 1999-11-30 2017-08-14 Mayo Foundation For Medical Education And Research B7-H1, a new immunoregulatory molecule
US20050074754A1 (en) * 2000-04-27 2005-04-07 Shoichi Okubo Novel protein and use thereof
US7700359B2 (en) 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
WO2002020598A1 (en) * 2000-07-28 2002-03-14 Michael Andrew Mcguckin Mucin
AU2001288606A1 (en) * 2000-08-31 2002-03-13 Millennium Pharmaceuticals, Inc. 8797, a human galactosyltransferase and uses thereof
WO2002064770A1 (en) * 2001-02-15 2002-08-22 Mochida Pharmaceutical Co., Ltd. Novel scavenger receptor class a protein
US6518055B2 (en) * 2001-03-26 2003-02-11 Applera Corporation Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
AU2002258941A1 (en) 2001-04-20 2002-11-05 Mayo Foundation For Medical Education And Research Methods of enhancing cell responsiveness
EP1430125A4 (en) 2001-05-03 2005-01-19 Childrens Medical Center SPERM-SPECIFIC CATIONIC CHANNEL, AND USES THEREOF
US6809104B2 (en) 2001-05-04 2004-10-26 Tularik Inc. Fused heterocyclic compounds
US20020173459A1 (en) * 2001-05-18 2002-11-21 Pe Corporation (Ny) Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof
US7208282B2 (en) 2001-05-31 2007-04-24 Merck & Co., Inc. Rhesus monkey, dog and ferret melanin-concentrating hormone type 2 receptor
CA2462790A1 (en) 2001-10-04 2003-04-10 Immunex Corporation Ul16 binding protein 4
WO2003054141A2 (en) 2001-10-22 2003-07-03 Children's Medical Center Corporation Sperm-specific cation channel, catsper2, and uses therefor
US8729248B2 (en) 2001-10-22 2014-05-20 Children's Medical Center Corporation Sperm-specific cation channel, CATSPER2, and uses therefor
JP4376629B2 (en) 2002-01-08 2009-12-02 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Gene products differentially expressed in cancerous breast cells and methods of use thereof
US8110668B2 (en) 2002-08-07 2012-02-07 Children's Medical Center Corporation Sperm-specific cation channel, catsper-3 and uses therefor
US20060123497A1 (en) 2002-08-07 2006-06-08 Children's Medical Center Corporation Sperm-specific cation channel, catsper-4, and uses therefor
NZ540328A (en) 2002-11-06 2008-02-29 Amgen Inc Fused heterocyclic compounds
PT2157192E (en) 2003-10-10 2013-11-28 Deutsches Krebsforsch COMPOSITIONS FOR DIAGNOSIS AND THERAPY OF DISEASES ASSOCIATED WITH ABERRANT EXPRESSION OF FUTRINAS (R-ESPONDINAS)
GB0417887D0 (en) 2004-08-11 2004-09-15 Ares Trading Sa Protein
JP5303146B2 (en) 2004-10-06 2013-10-02 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ B7-H1 and methods for diagnosis, prognosis and treatment of cancer
JP5535633B2 (en) 2006-09-29 2014-07-02 オンコメッド ファーマシューティカルズ インコーポレイテッド Compositions and methods for diagnosis and treatment of cancer
HUE027179T2 (en) 2006-10-20 2016-10-28 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Rspondins as modulators of angiogenesis and vasculogenesis
CA2691378A1 (en) 2007-07-02 2009-01-08 Oncomed Pharmaceuticals, Inc. Antibody against human r-spondin (rspo) and use thereof for inhibition of beta-catenin signaling and treatment of cancer
US20120039912A1 (en) 2009-04-15 2012-02-16 Galapagos Sasu Rspondin-3 inhibition in bone disorders
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
MX349198B (en) 2011-07-15 2017-07-18 Oncomed Pharmaceuticals Inc * AGENTS THAT JOIN THE R-SPONDIN PROTEINS (RSPO) AND USES OF THE SAME.
KR20150036603A (en) 2012-07-13 2015-04-07 온코메드 파마슈티칼스, 인크. Rspo3 binding agents and uses thereof
CA2961374A1 (en) 2014-09-16 2016-03-24 Oncomed Pharmaceuticals, Inc. Treatment of fibrotic diseases
CN112424228B (en) 2018-07-04 2024-08-09 豪夫迈·罗氏有限公司 Novel bispecific agonistic 4-1BB antigen binding molecules
CN118271445A (en) 2018-12-21 2024-07-02 豪夫迈·罗氏有限公司 Antibodies that bind to CD3
CN113272327A (en) 2018-12-30 2021-08-17 豪夫迈·罗氏有限公司 Anti-rabbit CD19 antibodies and methods of use thereof
KR20210118881A (en) 2019-01-22 2021-10-01 제넨테크, 인크. Immunoglobulin A Antibodies and Methods of Production and Use
WO2020176554A1 (en) 2019-02-28 2020-09-03 Genentech, Inc. Antibacterial peptides and methods of use
JP7301155B2 (en) 2019-04-12 2023-06-30 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Bispecific antigen-binding molecules containing lipocalin muteins
AR119382A1 (en) 2019-07-12 2021-12-15 Hoffmann La Roche PRE-TARGETING ANTIBODIES AND METHODS OF USE
AR119393A1 (en) 2019-07-15 2021-12-15 Hoffmann La Roche ANTIBODIES THAT BIND NKG2D
AR119997A1 (en) 2019-09-18 2022-01-26 Genentech Inc ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5 / KLK7 ANTIBODIES AND METHODS OF USE
KR20220100963A (en) 2019-12-18 2022-07-18 에프. 호프만-라 로슈 아게 Antibodies that bind to HLA-A2/MAGE-A4
WO2021123173A1 (en) 2019-12-20 2021-06-24 F. Hoffmann-La Roche Ag Il-37 fusion proteins and uses thereof
KR20220118527A (en) 2019-12-23 2022-08-25 제넨테크, 인크. Apolipoprotein L1-specific antibodies and methods of use
MX2022015206A (en) 2020-06-08 2023-01-05 Hoffmann La Roche Anti-hbv antibodies and methods of use.
KR20230025673A (en) 2020-06-19 2023-02-22 에프. 호프만-라 로슈 아게 Antibodies that bind to CD3 and FolR1
TWI811703B (en) 2020-06-19 2023-08-11 瑞士商赫孚孟拉羅股份公司 Antibodies binding to cd3 and cd19
WO2021255146A1 (en) 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Antibodies binding to cd3 and cea
JP2023529981A (en) 2020-06-19 2023-07-12 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Immunostimulatory Fc domain binding molecules
JP2023530961A (en) 2020-06-19 2023-07-20 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Antibody that binds to CD3
IL298921A (en) 2020-07-10 2023-02-01 Hoffmann La Roche Antibodies that bind to cancer cells and direct radionuclides to said cells
TW202216780A (en) 2020-07-17 2022-05-01 美商建南德克公司 Anti-notch2 antibodies and methods of use
CN116234831A (en) 2020-08-03 2023-06-06 豪夫迈·罗氏有限公司 Improved Antigen Binding Receptor
TW202233671A (en) 2020-10-20 2022-09-01 美商建南德克公司 Peg-conjugated anti-mertk antibodies and methods of use
WO2022084210A1 (en) 2020-10-20 2022-04-28 F. Hoffmann-La Roche Ag Combination therapy of pd-1 axis binding antagonists and lrrk2 inhitibors
CN116507640A (en) 2020-10-28 2023-07-28 豪夫迈·罗氏有限公司 Improved Antigen Binding Receptor
WO2022148853A1 (en) 2021-01-11 2022-07-14 F. Hoffmann-La Roche Ag Immunoconjugates
US20240082437A1 (en) 2021-01-12 2024-03-14 Hoffmann-La Roche Inc. Split antibodies which bind to cancer cells and target radionuclides to said cells
KR20230131205A (en) 2021-01-13 2023-09-12 에프. 호프만-라 로슈 아게 combination therapy
EP4288458A1 (en) 2021-02-03 2023-12-13 Genentech, Inc. Multispecific binding protein degrader platform and methods of use
CN117062839A (en) 2021-03-12 2023-11-14 基因泰克公司 Anti-KLK7 antibodies, anti-KLK5 antibodies, multispecific anti-KLK5/KLK7 antibodies and methods of use
EP4337317A1 (en) 2021-05-14 2024-03-20 Genentech, Inc. Agonists of trem2
JP2024521579A (en) 2021-06-09 2024-06-03 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Combination of a specific BRAF inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer - Patents.com
US20230048743A1 (en) 2021-07-12 2023-02-16 Genentech Inc. Structures for Reducing Antibody-Lipase Binding
CA3224853A1 (en) 2021-07-14 2023-01-19 Gautham GAMPA Anti-c-c motif chemokine receptor 8 (ccr8) antibodies and methods of use
EP4373859A1 (en) 2021-07-22 2024-05-29 F. Hoffmann-La Roche AG Heterodimeric fc domain antibodies
WO2023012147A1 (en) 2021-08-03 2023-02-09 F. Hoffmann-La Roche Ag Bispecific antibodies and methods of use
JP2024544885A (en) 2021-11-10 2024-12-05 ジェネンテック， インコーポレイテッド Anti-interleukin-33 antibodies and uses thereof
CA3237616A1 (en) 2021-11-25 2023-06-01 F. Hoffmann-La Roche Ag Improved antigen binding receptors
AR127887A1 (en) 2021-12-10 2024-03-06 Hoffmann La Roche ANTIBODIES THAT BIND CD3 AND PLAP
WO2023114829A1 (en) 2021-12-15 2023-06-22 Genentech, Inc. Stabilized il-18 polypeptides and uses thereof
CR20240246A (en) 2021-12-20 2024-07-19 Hoffmann La Roche AGONIST ANTI-LTBR ANTIBODIES AND BISPECIFIC ANTIBODIES THAT INCLUDE THEM
TW202340251A (en) 2022-01-19 2023-10-16 美商建南德克公司 Anti-notch2 antibodies and conjugates and methods of use
EP4493936A1 (en) 2022-03-14 2025-01-22 F. Hoffmann-La Roche AG Modulators of the g3bp2-tau interaction for the treatment of tau associated diseases
EP4499230A1 (en) 2022-03-25 2025-02-05 F. Hoffmann-La Roche AG Improved chimeric receptors
AR128876A1 (en) 2022-03-28 2024-06-19 Hoffmann La Roche ENHANCED FOLR1 PROTEASE ACTIVATABLE T LYMPHOCYTE BISPECIFIC ANTIBODIES
WO2023186756A1 (en) 2022-03-28 2023-10-05 F. Hoffmann-La Roche Ag Interferon gamma variants and antigen binding molecules comprising these
CA3246312A1 (en) 2022-04-01 2023-10-05 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
JP2025514645A (en) 2022-04-12 2025-05-09 エフ． ホフマン－ラ ロシュ アーゲー Fusion proteins targeted to the central nervous system
AU2022458320A1 (en) 2022-05-11 2024-11-28 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
EP4554978A1 (en) 2022-07-13 2025-05-21 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
CN119604530A (en) 2022-07-19 2025-03-11 基因泰克公司 Administration of Therapeutic Antibodies Using Anti-FCRH5/Anti-CD3 Bispecific Antibodies
AU2023312051A1 (en) 2022-07-22 2025-01-09 Genentech, Inc. Anti-steap1 antigen-binding molecules and uses thereof
JP2025533570A (en) 2022-09-28 2025-10-07 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Improved protease-activated T cell bispecific antibodies
CN119998323A (en) 2022-10-07 2025-05-13 基因泰克公司 Methods for treating cancer using anti-C-C motif chemokine receptor 8 (CCR8) antibodies
TW202426505A (en) 2022-10-25 2024-07-01 美商建南德克公司 Therapeutic and diagnostic methods for cancer
WO2024100170A1 (en) 2022-11-11 2024-05-16 F. Hoffmann-La Roche Ag Antibodies binding to hla-a*02/foxp3
JP2025539760A (en) 2022-11-15 2025-12-09 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト antigen binding molecule
CN120359214A (en) 2022-12-15 2025-07-22 豪夫迈·罗氏有限公司 Combination therapy for cancer treatment
KR20250134230A (en) 2023-01-18 2025-09-10 제넨테크, 인크. Multispecific antibodies and uses thereof
CN120569410A (en) 2023-01-25 2025-08-29 豪夫迈·罗氏有限公司 Antibodies that bind to CSF1R and CD3
EP4676519A1 (en) 2023-03-06 2026-01-14 F. Hoffmann-La Roche AG Combination therapy of an anti-egfrviii/anti-cd3 antibody and an tumor-targeted 4-1bb agonist
TW202446789A (en) 2023-03-31 2024-12-01 美商建南德克公司 Anti-alpha v beta 8 integrin antibodies and methods of use
CN120882744A (en) 2023-04-03 2025-10-31 豪夫迈·罗氏有限公司 Integrated agonist antibody
CN120917044A (en) 2023-04-03 2025-11-07 豪夫迈·罗氏有限公司 Agonist split antibody
AU2024270495A1 (en) 2023-05-05 2025-10-09 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
AU2024269754A1 (en) 2023-05-08 2025-10-23 F. Hoffmann-La Roche Ag Targeted interferon alpha fusion proteins and methods of use
CN121263435A (en) 2023-05-16 2026-01-02 豪夫迈·罗氏有限公司 PD-1-regulated IL-2 immune cytokines and their uses
WO2024261013A1 (en) 2023-06-21 2024-12-26 F. Hoffmann-La Roche Ag Combination therapy with fap-targeted lymphotoxin beta receptor agonists
WO2025021838A1 (en) 2023-07-26 2025-01-30 F. Hoffmann-La Roche Ag Antibodies binding to cd3
WO2025032071A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
WO2025032069A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
WO2025040567A1 (en) 2023-08-18 2025-02-27 F. Hoffmann-La Roche Ag Protease activatable fc domain binding molecules
TW202515615A (en) 2023-09-01 2025-04-16 美商建南德克公司 Methods for treating inflammatory bowel disease
AR133909A1 (en) 2023-09-25 2025-11-12 Hoffmann La Roche ANTIBODY THAT BINDS TO C3bBb
WO2025125118A1 (en) 2023-12-11 2025-06-19 F. Hoffmann-La Roche Ag Protease activatable fc domain binding molecules
WO2025125386A1 (en) 2023-12-14 2025-06-19 F. Hoffmann-La Roche Ag Antibodies that bind to folr1 and methods of use
WO2025132503A1 (en) 2023-12-20 2025-06-26 F. Hoffmann-La Roche Ag Antibodies binding to ceacam5
WO2025133042A2 (en) 2023-12-22 2025-06-26 F. Hoffmann-La Roche Ag Activatable fusion proteins and methods of use
WO2025151723A1 (en) 2024-01-12 2025-07-17 Genentech, Inc. Targeted protein degradation using bacterial e3 ligase
WO2025176614A1 (en) 2024-02-20 2025-08-28 F. Hoffmann-La Roche Ag Novel pre-targeting antibodies and uses thereof
WO2025181189A1 (en) 2024-03-01 2025-09-04 F. Hoffmann-La Roche Ag Antibodies binding to cd3
WO2025215060A1 (en) 2024-04-11 2025-10-16 F. Hoffmann-La Roche Ag Antibodies that specifically bind modified oligonucleotides
US20250376530A1 (en) 2024-05-17 2025-12-11 Genentech, Inc. Methods for treatment of inflammatory bowel disease with an anti-tl1a antibody
WO2025261943A1 (en) 2024-06-18 2025-12-26 F. Hoffmann-La Roche Ag Anti-cancer combinations comprising mosperafenib and folfox or folfiri

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5536637A (en) * 1993-04-07 1996-07-16 Genetics Institute, Inc. Method of screening for cDNA encoding novel secreted mammalian proteins in yeast
US5707829A (en) * 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
US5824504A (en) * 1996-09-26 1998-10-20 Elshourbagy; Nabil A. Human 7-transmembrane receptor and DNA

Also Published As

Publication number Publication date
CA2378403A1 (en) 2001-02-01
EP1196570A2 (en) 2002-04-17
JP2003505082A (en) 2003-02-12
WO2001007611A3 (en) 2001-08-23
WO2001007611A2 (en) 2001-02-01

Similar Documents

Publication Publication Date Title
AU6117000A (en) Novel polynucleotides and method of use thereof
AU4520801A (en) Novel substituted phenanthridinones and methods of use thereof
AU3867400A (en) Methods of using bioelastomers
AU2468401A (en) Underreamer and method of use
AU3215500A (en) Compounds and methods
AU7989400A (en) Compounds and methods
AU3917400A (en) Athletic apparatus and method of use
AU715620C (en) Therapeutic methods and uses
AU5886500A (en) Indolyl-benzimidazole antibacterials, and methods of use thereof
AU5800399A (en) Polish composition and method of use
AU5116100A (en) Connector and method of use of the connector
AU1812601A (en) Cover member and method of making same
AU9569998A (en) Photo-spectrometers, methods of use and manufacture
AU1083501A (en) Antibiotic-metal complex and methods
AUPO679297A0 (en) Rheology modification and modifiers
AU3476300A (en) Improved mouse and method of using
AU7134700A (en) Maize msi polynucleotides and methods of use
AUPP807799A0 (en) Polynucleotide and method
AU1755301A (en) Rollercross-type game and method thereof
AU2207001A (en) Novel compounds and process
AU3725500A (en) Hand-held bidet and method of use
AU5979300A (en) Angiopoietin-6 and uses thereof
AU1459500A (en) Dihydropyridine compounds and methods of use
AU2002221222A1 (en) Novel method and use
AU4598400A (en) Method of treatment

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase